OncRef

Clinical Trial: NCT04981899

PET-Adapted Low-Dose Nivolumab With NICE-40 for Relapsed/Refractory Classical Hodgkin Lymphoma

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:St. Petersburg State Pavlov Medical University
Information Provided By:St. Petersburg State Pavlov Medical University
Last Update Posted:2026-10-28

Study Overview

Brief Summary

Nivolumab is an anti-PD-1 antibody with high activity in patients with relapsed/refractory classical Hodgkin lymphoma (r/r cHL). A PET-adapted strategy using nivolumab with ICE added for patients without complete response has shown high response rates and favorable progression-free survival as a bridge to autologous stem cell transplantation, while allowing omission of salvage chemotherapy in a substantial proportion of patients. This study evaluates the safety and efficacy of a PET-adapted strategy using fixed-dose nivolumab 40 mg, with ifosfamide, carboplatin, and etoposide (NICE-40) administered to patients without complete response to nivolumab monotherapy.

Official Title

Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Conditions

Hodgkin Lymphoma

Intervention / Treatment

  • Drug: Nivolumab
  • Drug: Ifosfamide
  • Drug: Carboplatin
  • Drug: Etoposide

Other Study ID Numbers

  • r/r cHL NICE-40

Start Date (Actual)

2021-03-01

Primary Completion Date (Actual)

2026-05-01

Study Completion Date (Actual)

2026-09-15

Enrollment (Actual)

37

Study Type

Interventional

Phase

Phase 2